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SUMMARY
Cushing’s syndrome is a pathological condition associated with
excessive cortisol production, the commonest etiology being
Cushing’s disease. Corticosteroids in high doses have been used
in the management of Steven Johnson Syndrome (SJS) with
favourable outcome. We describe a patient with Cushing’s
disease who developed SJS, one week after taking sperulina a
product from sea-weed while waiting for transphenoidal
surgery. 
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INTRODUCTION
Steven Johnson syndrome (SJS) is a disorder of the skin and
mucous membrane, induced by exposure to drugs or
infections.  The incidence is about two cases per million
people per year.  Drug induced SJS usually begin one to three
weeks after the initiation of therapy.  The pathogenic
mechanisms for SJS have been proposed due to immune-
complex mediated hypersensitivity reaction in response to
the offending drug and its metabolites
1. Corticosteroid used
in the treatment of SJS is controversial, with studies showed
conflicting results. Tegelberg and colleagues reported an
improvement in SJS in their patients after administration of
high dose steroids
2. SJS also is reported to be more frequent in
the setting of compromised immune system.  Cushing’s
disease (CD) is a condition where the circulating serum
cortisol is elevated throughout the day.  Patients who are on
high dose corticosteroids or have excess of plasma cortisol are
immunocompromised and thus increased the risk of having
SJS.
CASE REPORT
A 40-year-old Chinese lady was referred to our institution for
Cushing’s syndrome.  She was diagnosed to have diabetes for
four months duration, associated with increased in weight.
Investigations confirmed Cushing’s disease (CD) and while
waiting for surgery, she developed extensive maculo popular
rashes including the mucous membrane. Skin biopsy
confirmed Steven Johnson Syndrome (SJS).  She gave history
of taking sperulina one week prior to the symptoms and also
history of taking lactulose about two days prior to the
development of Steven Johnson syndrome (SJS).  There was
no history of drug allergies before, and no symptoms to
suggest any viral infections.  Examination revealed an obese
lady with moon face, buffalo hump and fullness of
supraclavicular fossa.  There were no bruises or pigmentation.
She had proximal myopathy.  Blood pressure was 140/90
mmHg and pulse rate was 76/min regular. Systemic reviews
were normal. 
Laboratory studies revealed the following: haemoglobin 15.9
g/dl, total white count 7.1x10
9/l, platelet 169x10
9/l, serum
sodium 135 mmol/l, potassium 3.8 mmol/l, urea 5.8 mmol/l,
creatinine 52 mmol/l, normal liver profile, and glycosylated
haemoglobin at presentation was 8.1%.  The
electrocardiography and chest X-ray were normal.  Diagnostic
investigations were done and the results were: random
cortisol 981 nmol/l (normal 68-469 nmol/l), low dose
dexamethasone test showed serum cortisol was not
suppressible, cortisol post high dose dexamethasone was
suppressible, serum corticotrophin (ACTH) was 39 pg/ml
(normal < 46). Magnetic resonance imaging (MRI) of pituitary
gland showed no evidence of microadenoma.  Adrenal glands
were normal on computed tomography (CT). Inferior petrosal
sinus sampling (IPSS) was performed confirmed CD. Her
blood pressure and diabetes were controlled with nifedipine,
spironolactone and glucophage. 
Intravenous immunoglobulin (IVIG) was administered over
three days (total of 3gm/kg) to treat her SJS, along with
supportive therapy and close monitoring.  She was discharged
well six weeks later.  Following that, left pituitary
adenomectomy was performed, and random cortisol post
operatively was 120 nmol/l.  Her blood glucose normalized
and she no longer required anti hypertensive medications.
DISCUSSION
Cushing’s disease (CD) usually manifests by its’ metabolic
complications namely diabetes and hypertension. It is caused
by pituitary microadenoma which secretes
adrenocorticotrophic hormone (ACTH) which in turn
stimulates the adrenals to produce cortisol in excessive
amount.  The proportion of patients with CD in which no
pituitary tumor is identified on MRI varies between 20% and
50%.  Inferior petrosal sinus sampling allows the
determination of the site of a ACTH-secreting lesion.  Our
patient had a normal ACTH, but suppressible cortisol on high
dose dexamethasone suppression test suggesting CD.  We
were able to localize the adenoma, and appropriate
management was then carried out. 
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hypersensitivity reaction, and this is based on the
responsiveness of SJS to steroids.  Studies have shown that if
corticosteroids are tapered down rapidly, there is exacerbation
of SJS which is reversible by increasing the corticosteroids
dose
3.  On the other hand, a case control study reported that
the risk of developing SJS is increased with corticosteroid
therapy.  It is interesting to note that our patient developed
SJS whilst in hypercortisolism state. This denotes that
although much has been postulated regarding immune-
complex hypersensitivity reaction as the cause of SJS, the
pathogenic mechanisms of this disease remain unknown. 
High dose IVIG is now used to treat many autoimmune and
inflammatory diseases, and SJS is one of them. The IgG levels
in the serum and intralesional skin are raised after infusion of
IVIG, and this provide protection to the keratinocytes of the
patient
4. 
Our patient was taking sperulina, a sea-weed based
supplement about one week prior to development of SJS.
Drug-induced SJS usually begin one to three weeks after the
initiation of the offending drug.  This is very consistent with
the temporal response of known cell-mediated
hypersensitivity reactions. In the presence of
hypercortisolism, one would have assumed that the patient
would be less likely to mount a reaction due to the
immunocompromised state.  However, in severely altered
immune systems as in this patient, the offending agent like
sperulina may induce SJS.  There have been few reported cases
of patients developing SJS while receiving glucocorticoid
treatment for oral lichen planus.  SJS has also been reported
in a girl with systemic lupus erythematosus whilst on high
doses corticosteroid therapy
5 and SJS occurring in a patient
receiving treatment with cyclophosphamide and
prednisolone.
Corticosteroids have been proven as a treatment for SJS in
some cases
2 although IVIG has also been proposed as a
treatment in patient with this problem.  Pretreatment with
corticosteroids has also been shown to alleviate reactions to
the offending agent.  SJS is a disease that has been long
associated with multiple drugs, including supplements.
Supportive treatment remains the mainstay of the treatment
of SJS, together with early identification of the culprit drug
and immediate withdrawal. 
CONCLUSION
This case demonstrates that we do not fully understand the
pathogenic mechanisms of SJS. Despite the recommendation
of using high dose steroids for its treatment, excess cortisol in
the body alters immune systems and thus may induce SJS.
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